Fulcrum Therapeutics (NASDAQ:FULC) Upgraded to "Strong-Buy" at Leerink Partnrs

Leerink Partnrs upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC - Free Report) from a hold rating to a strong-buy rating in a research note released on Friday,Zacks.com reports.

Several other research firms have also commented on FULC. Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective for the company in a research note on Thursday, May 15th. Leerink Partners raised shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $4.00 to $12.00 in a research note on Friday. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Fulcrum Therapeutics presently has an average rating of "Hold" and an average target price of $5.83.

Fulcrum Therapeutics Stock Down 1.4%

NASDAQ FULC traded down $0.09 on Friday, reaching $6.35. The company had a trading volume of 492,934 shares, compared to its average volume of 970,476. The stock has a market capitalization of $342.77 million, a PE ratio of -20.48 and a beta of 2.29. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $10.13. The firm's 50 day moving average price is $4.10 and its 200 day moving average price is $3.93.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. On average, research analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Jump Financial LLC purchased a new stake in Fulcrum Therapeutics in the 1st quarter valued at about $30,000. Brooklyn Investment Group raised its stake in shares of Fulcrum Therapeutics by 209.7% during the first quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock valued at $35,000 after acquiring an additional 8,254 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Fulcrum Therapeutics during the fourth quarter valued at approximately $38,000. Virtu Financial LLC purchased a new stake in shares of Fulcrum Therapeutics in the first quarter valued at approximately $39,000. Finally, Mariner LLC bought a new position in Fulcrum Therapeutics in the fourth quarter worth approximately $78,000. Hedge funds and other institutional investors own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.